Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046735 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study OF CDC-501 in Patients With Solid Tumors
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00046735 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 24 participants.
The verdict
NCT00046735, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-06-01 |
| Est. Completion | 2006-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046735
The ClinicalTrials.gov registry entry for NCT00046735 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00046735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046735 about?
NCT00046735 is a clinical study titled "Phase 1 Study OF CDC-501 in Patients With Solid Tumors". To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.
What is the current status of trial NCT00046735?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2002-06-01. Estimated completion is 2006-09-28.
What interventions are being tested in trial NCT00046735?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00046735?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.